Background: Percutaneous ablation is a common treatment for colorectal liver metastasis (CLM). However, the effect of rat sarcoma viral oncogene homologue (RAS) mutation on outcome after ablation of CLMs is unclear. Conclusion: Mutant RAS is associated with an earlier and higher rate of local tumour progression in patients undergoing ablation of CLMs.
Introduction
Liver ablation is an effective treatment modality for patients with limited colorectal liver metastases (CLMs) 1 -7 . Current series 1 -4 demonstrate 5-year overall survival rates after ablation of CLMs ranging from 21 to 47⋅8 per cent. To achieve optimal results following liver ablation, local tumour progression should be minimized 1, 2 . Small size and limited number of CLMs 4 -8 , and adequate ablation margins 2, 9, 10 have been positively correlated with low rates of local tumour progression. Similarly, the existing surgical literature demonstrates that resection of CLMs with negative margins is associated with improved rates of overall survival 11, 12 , whereas resection with positive margins is strongly associated with a worse prognosis, even with the use of modern preoperative chemotherapy regimens 13 . Despite the importance of adequate ablation and resection margins on the local outcomes of treated CLMs, the biological factors associated with poor local tumour control following local therapies for CLM remain unclear, and further investigations are needed.
Rat sarcoma viral oncogene homologue (RAS) mutations are found in up to 40 per cent of patients with colorectal cancer, and have been associated with reduced survival after resection of primary colorectal cancer and CLMs 14 -17 . It has been reported that mutant RAS is associated with an inferior response to preoperative chemotherapy and worse survival in patients with resectable CLMs 18 , and with a more invasive and migratory tumour biology 19 . Additionally, a recent study 20 demonstrated that mutant RAS is associated with positive and narrow resection margins in patients undergoing resection of CLM.
On the basis of these findings, it was hypothesized that the local tumour progression rate after ablation of CLMs is higher in patients with mutant RAS than in patients with wild-type RAS.
Methods
This single-institution retrospective study was compliant with the Health Insurance Portability and Accountability Act, and approved by the Institutional Review Board of the University of Texas MD Anderson Cancer Center, with a waiver of informed consent (IRB protocol PA15-0566). The institution's retrospectively compiled liver ablation database, maintained by the Department of Interventional Radiology, was searched to identify patients who underwent percutaneous ablation of CLMs from 2004 to 2015, had known RAS status, did not undergo combined transarterial therapies or subsequent surgical resection, and had imaging follow-up to at least 6 months after percutaneous ablation.
Variables extracted from the database or updated by review of electronic medical records for each patient included: sex, age, location of primary tumour, lymph node status of primary tumour, number and type of preablation chemotherapy regimens (if any), disease-free survival interval between diagnosis of primary cancer and appearance of CLM, preablation carcinoembryonic antigen (CEA) level, presence of other sites of metastasis at the time of percutaneous ablation of CLM, clinical score as defined by Fong and colleagues 11 , time between hepatic resection and CLM ablation, RAS mutation status, and site of any recurrence after ablation. Variables extracted for each ablated CLM were: number of ablation sessions, largest diameter of the lesion at first ablation session, time from CLM discovery to first ablation session, ablation modality (radiofrequency or microwave), minimum ablation margin (less than 5 mm, 5-10 mm, or more than 10 mm), CLM location in relation to the liver capsule (subcapsular (within 1 cm of the liver capsule) or non-subcapsular), CLM located adjacent to major vessel (vessel more than 3 mm in diameter) (yes or no), and presence or absence of local tumour progression. In patients treated with preablation chemotherapy, change in lesion size was assessed by cross-sectional imaging before and after chemotherapy.
Eligibility criteria for percutaneous ablation, and technique
Patients were eligible for percutaneous ablation of CLM if they had no more than five CLMs, ideally measuring no more than 5 cm each 21 . All procedures were performed with the goal of completely ablating each CLM, but during the period of study accrual there was no consensus regarding acceptable minimum ablation margins. All percutaneous hepatic ablation procedures were performed by one of four interventional radiologists, with the patient under general anaesthesia and with continuous haemodynamic monitoring by an anaesthetist. CT guidance was employed. CT fluoroscopy or ultrasonography was used when real-time imaging was deemed appropriate. Ablations were performed with radiofrequency (82 sessions for 77 CLMs) (Cool-tip™ RF ablation system; Covidien, Boulder, Colorado, USA) or microwave (61 sessions for 60 CLMs) (Certus ® probe, Certus ® 140 2⋅4-GHz microwave ablation system; NeuWave, Madison, Wisconsin, USA) according to the operator's choice. Patients were discharged home within 24 h of the procedure.
Imaging follow-up and assessment of response
Imaging assessment was performed independently by two readers, and discrepancies in interpretation were resolved by consensus. All available preablation contrast-enhanced CT and MRI or PET-CT images were reviewed to identify the date of diagnosis of each CLM. If a CLM was present on the first cross-sectional imaging study available in the electronic medical record, the date of this study was considered the date of diagnosis of that particular CLM.
The initial postablation cross-sectional imaging assessment of the efficacy of ablation was performed within 4-8 weeks after ablation. The width of the minimum ablation margin was assessed by comparing the distances of the index tumour on the baseline cross-sectional imaging and the ablation zone on the initial postablation cross-sectional imaging from intrahepatic landmarks on portal venous phase CT images, as described previously 2 . After the initial postablation imaging assessment, further assessments were performed at 2-4-month intervals until patient death or loss to follow-up.
To describe ablation endpoints, the standardized terminology and reporting criteria initially described by Goldberg et al. 22 , and later updated by Ahmed and colleagues 23 , were employed. Residual unablated tumour was defined as irregular peripheral or nodular enhancement within 1 cm of the ablated area on the initial postablation cross-sectional image. Local tumour progression was defined as the appearance of tumour foci within 1 cm of the edge of the ablation zone on contrast-enhanced CT or MRI after at least one contrast-enhanced postablation follow-up study had documented adequate ablation Kaplan-Meier analysis of a local tumour progression-free, b recurrence-free and c overall survival after ablation of colorectal liver metastases in patients with wild-type and mutant RAS status. a P = 0⋅001, b P = 0⋅013, c P = 0⋅013 (log rank test) and the absence of viable tissue in the target tumour and surrounding ablation margin.
RAS mutation profiling
RAS mutation profiling was performed as described previously 20 . In brief, DNA from the primary tumour or from a CLM was subjected to a routine PCR-based primer extension assay. Screening for mutations in KRAS codons 12 and 13 was performed in all patients, and screening for mutations in KRAS codons 61 and 146, and NRAS codons 12, 13 and 61 was performed in the majority of patients in the most recent years of the study. The lower detection limit of the assay was approximately one mutant allele in a background of nine wild-type alleles. Single mutations in the various codons of KRAS and NRAS were analysed together and reported as RAS mutations.
Statistical analysis
Continuous variables were compared using the Wilcoxon rank sum test, and categorical variables with the χ 2 test. Local tumour progression-free survival was measured in months from the date of last ablation session to the date when local tumour progression was detected on cross-sectional imaging, or last follow-up. Recurrence-free survival was measured in months from the date of ablation to the date of detection of any organ recurrence on cross-sectional imaging, or last follow-up. Overall survival was measured in months from the date of ablation to the date of death, or last follow-up. Survival curves were generated using the Kaplan-Meier method, and differences between curves evaluated with the log rank test. Univariable and multivariable analyses to identify predictors of local tumour progression-free survival were performed using Cox proportional hazards regression models. Variables with P < 0⋅100 in univariable analysis were entered into each multivariable analysis. P < 0⋅050 was considered statistically significant in all analyses. Statistical analysis was performed with JMP ® software version 12.1.0 (SAS Institute, Cary, North Carolina, USA).
Results
A total of 149 patients with CLM underwent percutaneous liver ablation during the study interval. Of these, 57 patients were excluded from the analysis because of undetermined RAS mutation status (38), use of cryoablation (8), use of transarterial chemoembolization (4) or surgical resection (3) of the ablated lesion, or lack of cross-sectional imaging after ablation (4). After these exclusions, 92 patients who underwent percutaneous ablation of 137 CLMs were eligible for analysis. A total of 135 CLMs (98⋅5 per cent) were successfully eradicated following the initial ablation procedure; for two CLMs, residual unablated tumour was detected on the first cross-sectional imaging study after percutaneous ablation and was successfully ablated following an additional ablation session.
Local tumour progression
Of the 92 patients, 22 (24 per cent) had local tumour progression, involving 25 (18⋅2 per cent) of the 137 ablated CLMs. Some 17 of these 22 patients showed concurrent progression with other sites of intrahepatic or extrahepatic metastasis and were treated with systemic therapy. In the remaining five patients, the local tumour progression was deemed unsafe for repeat ablation owing to tumour size and/or proximity to critical structures.
Patient, tumour and treatment characteristics by RAS mutation status
Mutant RAS was detected in 36 patients (39 per cent). Patient, tumour and treatment characteristics by RAS status are summarized in Table 1 . The median age was 59 (range 28-92) years, and there were 62 men. The primary tumour was located in the colon in 76 patients (83 per cent) and in the rectum in 16 (17 per cent). Positive lymph nodes were noted at diagnosis of the primary tumour in 64 patients (70 per cent).
Patients with mutant RAS were associated with a higher rate of local tumour progression (14 per cent in patients with wild-type RAS versus 39 per cent in those with mutant RAS; P = 0⋅007) ( Table 1) . Patients with mutant and wild-type RAS did not differ with respect to other demographic, clinical or imaging characteristics, including sex, age, history of hepatic resection, location of the primary tumour, lymph node status of the primary tumour or ablation modality.
Preablation chemotherapy was used in 59 patients (64 per cent), and patients with wild-type and mutant RAS did not differ significantly in terms of the frequency of use of preablation chemotherapy, number of cycles and regimens, and types of preablation chemotherapy. Patients with wild-type and mutant RAS did not differ with respect to time between CLM discovery and first ablation session, or number, location and size of CLMs treated with ablation ( Table 1) .
Influence of RAS mutation status on survival
The median (range) follow-up interval was not significantly different between patients with wild-type RAS and those with mutant RAS: 35 (6⋅1-138) and 28 (6⋅0-133) months respectively (P = 0⋅626).
Three-year local tumour progression-free, recurrencefree and overall survival rates were significantly worse in patients with mutant RAS than in those with wild-type RAS (Fig. 1) . Of patients with mutant RAS, 58 per cent experienced local tumour progression within 2 years (Fig. 1a) . Among the 56 patients with wild-type RAS, 24 (43 per cent) developed one or more new CLMs on the liver distant from the ablated lesion(s) on imaging follow-up; four of these 24 patients presented with local tumour progression at previously ablated CLMs. Among the 36 patients with mutant RAS, 20 (56 per cent) developed one or more new CLMs distant from the ablated lesion(s) on imaging follow-up; 12 of these 20 patients also had local tumour progression at previously ablated CLMs. Analysis of the 25 ablated CLMs with local tumour progression demonstrated that this progression occurred earlier in patients with mutant RAS than in those with wild-type RAS. Where local tumour progression occurred, the size of the CLMs was smaller in patients with mutant RAS than in patients with wild-type RAS (Fig. 2) .
Predictors of local tumour progression-free survival
On multivariable analysis of factors associated with local tumour progression-free survival, independent predictors of worse outcome were minimum ablation margin less than 5 mm (hazard ratio (HR) 2⋅48, 95 per cent c.i. 1⋅31 to 4⋅72; P = 0⋅006) and mutant RAS (HR 3⋅01, 1⋅60 to 5⋅77; P = 0⋅001) ( Table 2 ).
In the subgroup of 56 patients treated with a minimum ablation margin of at least 5 mm, the actuarial 3-year local tumour progression-free survival rate of patients with mutant RAS was 54 per cent, compared with 77 per cent in those with wild-type RAS (P = 0⋅037) (Fig. 3a) . In the subgroup of 64 patients undergoing ablation of CLMs with a diameter of less than 2 cm, the 3-year local tumour progression-free survival rate was significantly worse in those with mutant RAS (35 per cent versus 81 per cent in patients with the wild-type allele; P < 0⋅001) (Fig. 3b) .
Discussion
In this study, local tumour progression-free survival following percutaneous ablation of CLMs was worse in patients with mutant RAS than in those with wild-type RAS. In patients with mutant RAS, the actuarial local tumour progression rate at 2 years was 58 per cent, significantly higher than that in patients with wild-type RAS (24 per cent).
RAS mutation status is increasingly being recognized as a biological predictor of patterns of response and recurrence after chemotherapy and liver resection of CLMs 15, 18, 24 , and the present study shows that outcomes are also worse following liver ablation in patients with a RAS mutation. In this study, there were no significant differences between patients with wild-type RAS and patients with mutant RAS with respect to ablation modality, preablation chemotherapy regimen, and extent of primary colorectal cancer and CLMs. Importantly, all ablations were performed without consideration of RAS status. In agreement with the present study, Brudvik et al. 20 showed a higher rate of positive margins following resection of CLMs among patients with mutant RAS than in patients with wild-type RAS, suggesting different pathological and phenotypic features in patients with mutant and wild-type RAS. Although analysis of KRAS codons 12 and 13 was performed in all patients, analysis of KRAS codons 61 and 146, and NRAS codons 12, 13 and 61, was undertaken in the later years of the study. However, mutations outside KRAS codons 12 and 13 comprise less than 10 per cent of RAS mutations, and their inclusion would likely increase the observed differences in survival between groups 20, 25 .
This study identified a minimum ablation margin of less than 5 mm as the one local factor independently associated with local tumour progression-free survival after CLM ablation. Size of the ablated CLM of 2 cm or more was associated with worse local tumour progression-free survival in univariable, but not multivariable, analysis. In addition to these local factors, this study showed that RAS mutation status, a biological factor, was an independent predictor of local tumour progression-free survival after CLM ablation. Previous reports 2, 9, 10, 26 have shown the prognostic value of lesion size and ablation margin, but the present study also found an association between RAS mutation status and local tumour progression-free survival following CLM ablation. Notably, the present multivariable analysis suggests that factors such as nodal status of the primary colorectal cancer, preablation CEA level, and metachronous/synchronous CLMs, which were traditionally reported to be associated with oncological outcome 27 , are less significant predictors of local tumour progression-free survival after CLM ablation.
This study has several limitations. First, the retrospective selection of patients in whom RAS status had been determined might have created a selection bias. However, percutaneous ablation and imaging assessment for local tumour progression were performed without consideration of RAS status. Most patients (60 per cent) had a history of surgical resection, which creates the potential for selection bias. However, rates of postresection ablation were in keeping with those available in the literature 2 . Most patients (64 per cent) underwent preablation chemotherapy, with various regimens. Despite the heterogeneity of chemotherapy, there were no differences between patients with wild-type RAS and those with mutant RAS in terms of presence or absence of chemotherapy and type of regimen. Finally, the minimum follow-up was 6 months, and a few patients with local recurrence beyond 6 months may thus not have been captured. However, the median length of follow-up was over 2 years for both RAS mutated and wild-type groups.
This study has shown that RAS mutations are associated with worse local tumour progression-free survival after percutaneous ablation of CLMs. Although larger ablation margins might be associated with lower local tumour progression rates following CLM ablation in patients with mutant RAS, no specific recommendations can be made regarding the optimal ablation margin for such CLMs, and further investigation is warranted.
